See more : Autolite (India) Limited (AUTOLITIND.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Paratek Pharmaceuticals, Inc. (PRTK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paratek Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Akari Therapeutics, Plc (AKTX) Income Statement Analysis – Financial Results
- PT Kalbe Farma Tbk. (PTKFF) Income Statement Analysis – Financial Results
- Grupo Financiero Inbursa, S.A.B. de C.V. (GPFOF) Income Statement Analysis – Financial Results
- Golden Sun Education Group Limited (GSUN) Income Statement Analysis – Financial Results
- Globe International Limited (GLB.AX) Income Statement Analysis – Financial Results
Paratek Pharmaceuticals, Inc. (PRTK)
About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150.79M | 120.95M | 43.52M | 16.54M | 17.12M | 12.62M | 29.00K | 0.00 | 4.34M | 1.75M | 11.03M | 19.69M | 12.50M | 5.21M | 60.62M | 16.68M | 371.00K | 56.00K | 1.12M | 1.33M | 371.00K | 0.00 |
| Cost of Revenue | 23.06M | 21.54M | 8.65M | 3.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.97M | 2.22M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 127.73M | 99.42M | 34.87M | 13.06M | 17.12M | 12.62M | 29.00K | 0.00 | 4.34M | 1.75M | 11.03M | 19.69M | 10.53M | 2.98M | 60.62M | 16.68M | 371.00K | 56.00K | 1.12M | 1.33M | 371.00K | 0.00 |
| Gross Profit Ratio | 84.71% | 82.20% | 80.12% | 78.94% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 84.26% | 57.30% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 37.82M | 30.35M | 23.92M | 39.55M | 57.51M | 60.07M | 83.46M | 50.77M | 5.01M | 6.90M | 11.19M | 11.27M | 10.68M | 9.01M | 11.68M | 36.06M | 21.81M | 17.67M | 14.69M | 0.00 | 4.04M | 1.04M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 63.66M | 36.97M | 26.40M | 19.99M | 5.85M | 12.43M | 10.26M | 0.00 | 7.92M | 16.05M | 16.90M | 17.28M | 11.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.82M | 1.43M | 0.00 | 3.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 145.60M | 119.40M | 89.86M | 89.14M | 63.66M | 36.97M | 26.40M | 19.99M | 5.85M | 19.25M | 11.69M | 12.19M | 11.04M | 16.05M | 16.90M | 17.28M | 11.31M | 7.25M | 5.21M | 0.00 | 2.21M | 602.00K |
| Other Expenses | -9.48M | -9.21M | -3.41M | -31.00K | -44.00K | -34.00K | 4.00K | -37.00K | -299.00K | 2.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 173.94M | 140.55M | 110.37M | 128.69M | 121.17M | 97.04M | 109.86M | 70.75M | 10.86M | 26.16M | 22.88M | 23.46M | 21.72M | 25.06M | 28.58M | 53.33M | 33.12M | 24.92M | 19.90M | 0.00 | 6.25M | 1.65M |
| Cost & Expenses | 197.00M | 162.08M | 119.02M | 132.17M | 121.17M | 97.04M | 109.86M | 70.75M | 10.86M | 26.16M | 22.88M | 23.46M | 21.72M | 25.06M | 28.58M | 53.33M | 33.12M | 24.92M | 19.90M | 0.00 | 6.25M | 1.65M |
| Interest Income | 752.00K | 66.00K | 1.52M | 3.57M | 3.26M | 1.38M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 79.00K | 127.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.12M | 17.41M | 20.24M | 16.40M | 10.99M | 5.08M | 3.22M | 770.00K | 718.00K | 0.00 | 0.00 | 9.00K | 12.00K | 179.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.31M | 445.00K | 1.57M | 3.54M | -1.07M | 1.27M | 2.30M | 714.00K | 196.00K | 90.00K | 229.00K | 357.00K | 500.00K | 550.00K | 1.12M | 516.00K | 693.00K | 521.00K | 88.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -44.90M | -40.69M | -73.93M | -112.09M | -100.83M | -83.08M | -106.46M | -70.79M | -6.62M | -21.45M | -11.86M | -3.76M | -8.53M | -17.79M | 33.16M | -36.14M | -32.05M | -24.34M | -18.69M | 1.33M | -5.88M | -1.65M |
| EBITDA Ratio | -29.78% | -33.64% | -169.89% | -677.50% | -589.08% | -658.51% | -367,086.21% | 0.00% | -152.53% | -1,227.65% | -107.54% | -19.11% | -68.21% | -341.61% | 54.71% | -216.60% | -8,639.08% | -43,469.64% | -1,668.84% | 100.00% | -1,584.37% | 0.00% |
| Operating Income | -46.21M | -41.13M | -75.50M | -115.63M | -104.09M | -84.58M | -109.49M | -70.05M | -7.80M | -27.37M | -11.86M | -3.76M | -9.22M | -22.07M | 32.04M | -36.65M | -32.74M | -24.86M | -18.78M | 1.33M | -5.88M | -1.65M |
| Operating Income Ratio | -30.65% | -34.01% | -173.50% | -698.92% | -608.08% | -670.42% | -377,537.93% | 0.00% | -179.59% | -1,566.74% | -107.54% | -19.11% | -73.78% | -423.79% | 52.86% | -219.69% | -8,825.88% | -44,400.00% | -1,676.70% | 100.00% | -1,584.37% | 0.00% |
| Total Other Income/Expenses | -17.30M | -17.35M | -21.04M | -12.86M | -7.77M | -3.74M | -2.15M | -807.00K | -10.04M | -75.00K | -159.00K | -116.00K | -81.00K | 271.00K | 2.78M | 4.12M | 3.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -63.51M | -58.48M | -96.54M | -128.49M | -111.85M | -88.32M | -111.64M | -70.86M | -17.84M | -27.45M | -12.02M | -3.95M | -9.42M | -24.13M | 34.82M | -32.53M | -29.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -42.12% | -48.35% | -221.85% | -776.65% | -653.47% | -700.03% | -384,951.72% | 0.00% | -410.76% | -1,571.04% | -108.98% | -20.06% | -75.34% | -463.27% | 57.44% | -194.99% | -7,985.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 57.00K | 600.00K | 19.72M | 301.00K | 502.00K | 753.00K | 3.23M | 19.00K | 419.00K | 2.95M | -229.00K | -427.00K | 81.00K | 1.40M | -2.78M | -4.12M | -3.12M | -1.06M | -827.00K | 12.78M | 5.64M | 1.58M |
| Net Income | -63.57M | -59.08M | -116.26M | -128.79M | -112.36M | -89.07M | -111.64M | -70.86M | -17.84M | -27.45M | -12.02M | -3.88M | -9.30M | -21.80M | 34.82M | -32.53M | -29.63M | -23.81M | -17.95M | -12.78M | -5.64M | -1.58M |
| Net Income Ratio | -42.16% | -48.85% | -267.16% | -778.47% | -656.40% | -706.00% | -384,951.72% | 0.00% | -410.76% | -1,571.04% | -108.98% | -19.70% | -74.42% | -418.59% | 57.44% | -194.99% | -7,985.98% | -42,508.93% | -1,602.86% | -960.53% | -1,519.14% | 0.00% |
| EPS | -1.17 | -1.22 | -2.63 | -3.93 | -3.57 | -3.32 | -5.51 | -4.29 | -7.05 | -17.54 | -8.46 | -3.44 | -8.32 | -21.50 | -597.24 | -403.95 | -118.58 | -1.02K | -993.69 | -849.01 | -414.93 | -133.99 |
| EPS Diluted | -1.17 | -1.22 | -2.63 | -3.93 | -3.57 | -3.32 | -5.51 | -4.29 | -7.05 | -17.54 | -8.46 | -3.44 | -8.32 | -21.50 | -597.24 | -403.95 | -118.58 | -1.02K | -993.69 | -849.01 | -414.93 | -133.99 |
| Weighted Avg Shares Out | 54.39M | 48.42M | 44.17M | 32.79M | 31.51M | 26.83M | 20.25M | 16.50M | 2.53M | 1.56M | 1.42M | 1.13M | 1.12M | 1.01M | 33.42K | 80.53K | 249.85K | 23.30K | 18.07K | 15.05K | 13.58K | 11.80K |
| Weighted Avg Shares Out (Dil) | 54.39M | 48.42M | 44.17M | 32.79M | 31.51M | 26.83M | 20.25M | 16.50M | 2.53M | 1.56M | 1.42M | 1.13M | 1.12M | 1.01M | 33.42K | 80.53K | 249.85K | 23.30K | 18.07K | 15.05K | 13.58K | 11.80K |
Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital, community and public health settings, announces that its U.S. supply and manufacturing capabilities...
Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
First randomized placebo-controlled trial in NTM abscessus Symptom-based endpoints showed favorable improvement in frequency and severity of the most common symptoms Microbiologic endpoints showed higher conversion to negative sputum culture, without emergence of resistance to omadacycline In this 12-week study,...
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies...
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-Tolerated Largest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last Decade Label Update Discussions with FDA to Begin as Early as 4Q2024 BOSTON, July...
Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces...
Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk , on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million.
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company...
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary...
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S
BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading...
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy...
Source: https://incomestatements.info
Category: Stock Reports